Omnicell, Inc. (OMCL) Given Average Recommendation of “Buy” by Brokerages
Shares of Omnicell, Inc. (NASDAQ:OMCL) have been given an average rating of “Buy” by the twelve brokerages that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $47.00.
OMCL has been the subject of a number of recent analyst reports. TheStreet downgraded Omnicell from a “b-” rating to a “c+” rating in a report on Thursday, May 4th. ValuEngine upgraded Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a report on Friday, May 26th. Piper Jaffray Companies cut Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 target price for the company. in a research note on Friday, April 21st. Finally, CIBC boosted their target price on Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, April 26th.
In other Omnicell news, Chairman Randall A. Lipps sold 9,900 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $43.00, for a total value of $425,700.00. Following the completion of the transaction, the chairman now directly owns 208,982 shares of the company’s stock, valued at $8,986,226. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director James T. Judson sold 12,148 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $41.50, for a total value of $504,142.00. Following the completion of the transaction, the director now directly owns 19,130 shares of the company’s stock, valued at $793,895. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,473 shares of company stock valued at $2,869,438. Insiders own 3.75% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of OMCL. Russell Investments Group Ltd. purchased a new position in Omnicell during the fourth quarter valued at $1,628,000. Comerica Bank boosted its position in Omnicell by 2.4% in the fourth quarter. Comerica Bank now owns 68,676 shares of the company’s stock valued at $2,290,000 after buying an additional 1,634 shares in the last quarter. State Street Corp boosted its position in Omnicell by 8.1% in the fourth quarter. State Street Corp now owns 802,579 shares of the company’s stock valued at $27,210,000 after buying an additional 60,375 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Omnicell by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,798,592 shares of the company’s stock valued at $60,972,000 after buying an additional 47,138 shares in the last quarter. Finally, Martingale Asset Management L P boosted its position in Omnicell by 83.5% in the fourth quarter. Martingale Asset Management L P now owns 125,912 shares of the company’s stock valued at $4,269,000 after buying an additional 57,300 shares in the last quarter. 96.35% of the stock is owned by institutional investors.
Shares of Omnicell (NASDAQ OMCL) traded down 1.15% during midday trading on Monday, reaching $42.85. The company’s stock had a trading volume of 86,043 shares. The company’s market cap is $1.59 billion. Omnicell has a 12 month low of $30.35 and a 12 month high of $43.50. The stock has a 50-day moving average of $41.55 and a 200 day moving average of $38.06.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, May 4th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.36. The business had revenue of $150.90 million during the quarter, compared to the consensus estimate of $152.63 million. Omnicell had a positive return on equity of 2.66% and a negative net margin of 1.45%. The firm’s revenue was down 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.35 earnings per share. On average, analysts predict that Omnicell will post $1.28 earnings per share for the current fiscal year.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.